💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Lansoprazole

CHEMBL480 Phase 4 Aprobado Small molecule
Half-Life
1.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
369.4 g/mol
LogP
2.8
Phase
4

A proton pump inhibitor (PPI) used to treat acid-related conditions including GERD, stomach ulcers, and Zollinger-Ellison syndrome. It works by irreversibly blocking the hydrogen-potassium ATPase enzyme in stomach cells to reduce acid production.

Peso molecular

369,3620 g/mol

LogP

2,80

TPSA

87,10 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Asma Cáncer colorrectal Cáncer de mama Cáncer de pulmón de células no pequeñas Diabetes tipo 2 Dolor crónico Enfermedad infecciosa Enfermedad por reflujo gastroesofágico Enfermedad pulmonar obstructiva crónica Gota Linfoma Manejo del dolor

Clases de fármacos

A — A - Aparato digestivo y metabolismo

Mecanismo de acción

Proton pump inhibitor.

Pharmacokinetics (PK)

Half-Life 1.5 hours

Pharmacodynamics (PD)

Mecanismo

Proton pump inhibitor.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1

                

                

                
                

                    
InChI

                    
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H14F3N3O2S

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
Enlaces Rotables

                        
5

                    

                    
                    
                    

                        
Átomos Pesados

                        
25

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ATP4A (Bomba de protones (H+/K+-ATPasa))
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Lansoprazole + Clopidogrel
                            
                        

                        
                        
Lansoprazole, like omeprazole, inhibits CYP2C19 and reduces clopidogrel's antiplatelet efficacy, potentially increasing cardiovascular event risk.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
A proton pump inhibitor (PPI) used to treat acid-related conditions including GERD, stomach ulcers, and Zollinger-Ellison syndrome. It works by irreversibly blocking the hydrogen-potassium ATPase enzyme in stomach cells to reduce acid production.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Proton pump inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Lansoprazole: Half-life: 1.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Lansoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Insulin Glargine
                            Protein
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL480.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3883.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.